April 17, 2019
Anti-Alpaca IgG, Subclass and VHH domain secondary antibodies to optimize VHH (single-domain) antibody development and application
Jackson ImmunoResearch, manufacturer of secondary antibodies for the life science market, announces a new range of products for scientists developing single-domain VHH antibodies.
The new Anti-Alpaca secondary antibody product line targets the IgG repertoire of camelid immunoglobulins, including whole molecule, subclass and VHH domain specificities. They are raised against alpaca and cross-react with llama.
Anti-Alpaca IgG subclasses 2+3 specific antibodies enable scientists to monitor immune response and pinpoint the optimal B cell harvest timeframe. Anti-Alpaca VHH domain antibodies were also developed to detect single-domain antibodies across all immunotechniques and will be an indispensable tool in diagnostics and drug development.
David A. Fancy PhD, chief operating officer, commented “Jackson ImmunoResearch is very excited to bring anti-camelid secondary antibodies to the marketplace. The single-domain antibody market is rapidly expanding. These antibodies are 1/10th the size of canonical immunoglobulins making them ideal for drug delivery and super-resolution imaging, among many other potential uses. Secondary antibodies for VHH discovery are designed to support research needs, reduce project time and improve success rates.”
Anti-Alpaca IgG secondary antibodies are now available for purchase directly from Jackson ImmunoResearch in the USA and Europe, or through global distribution partners.
More information is available at https://www.jacksonimmuno.com/technical/products/VHH-Discovery.
About Jackson ImmunoResearch
Jackson ImmunoResearch specializes in secondary antibodies for life science applications. Their reputation as a trusted supplier is founded on 37 years of experience in immunoglobulin purification, conjugation and lyophilization.
October 2, 2023
Takara Bio Inc. announces that it has entered into a License Agreement with non-profit/charity organization, Fondazione Telethon ETS (“Telethon”) (htt...
September 28, 2023
The new biotech will use its unique development approach to bring transformative cell therapies to market, starting with a promising treatment for Ret...
September 27, 2023
PCR Biosystems, a leading PCR reagent developer, has launched a new range of Bst polymerase reagents that offer greater sensitivity, speed, and specif...
Life Science Newswire is a division of BioStrata.
BioStrata Ltd., Endurance House, Vision Park, Histon, Cambridge, CB249ZR,
Company registration: 8233225